PMID- 22939229
OWN - NLM
STAT- MEDLINE
DCOM- 20130110
LR  - 20131121
IS  - 2210-7762 (Print)
VI  - 205
IP  - 10
DP  - 2012 Oct
TI  - Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free 
      survival for chronic lymphocytic leukemia patients who have an isolated deletion 
      13q abnormality.
PG  - 523-7
LID - S2210-7762(12)00152-4 [pii]
LID - 10.1016/j.cancergen.2012.05.011 [doi]
AB  - Immunoglobulin heavy chain translocations (t(IGH@)) are suggested to portend a 
      poor prognosis in chronic lymphocytic leukemia (CLL). To determine the clinical 
      significance of a t(IGH@) on CLL-specific cytogenetic abnormalities, we analyzed 
      the outcomes of 142 CLL patients referred for fluorescence in situ hybridization 
      (FISH) analysis with our standard FISH panel, which includes testing for a 
      t(IGH@). Whereas patients with unfavorable (deletion 17p, deletion 11q) and 
      intermediate (trisomy 12, normal FISH) cytogenetics with concomitant t(IGH@) had 
      similar median treatment-free survival (TFS) as those without a t(IGH@), patients 
      with deletion 13q (del13q) and a t(IGH@) had significantly worse TFS than those 
      without a t(IGH@): median TFS 4.7 versus 8.0 years, P = 0.03 (hazard ratio 4.21, 
      95% confidence interval 1.06-16.69 y, P = 0.04 in multivariate analysis after 
      adjusting for age, sex, Rai stage, and white blood cell count). The presence of a 
      t(IGH@) further stratified patients with del13q into two prognostic entities, 
      whereby outcomes of those with coexistent del13q and a t(IGH@) were similar to 
      outcomes of those with high risk cytogenetics. Knowledge of the t(IGH@) status in 
      CLL is therefore of clinical importance, as del13q patients with concomitant 
      t(IGH@) may not retain the previously expected favorable outcome.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Gerrie, Alina S
AU  - Gerrie AS
AD  - Division of Hematology, University of British Columbia, Vancouver, Canada.
FAU - Bruyere, Helene
AU  - Bruyere H
FAU - Chan, Mary Joyce
AU  - Chan MJ
FAU - Dalal, Chinmay B
AU  - Dalal CB
FAU - Ramadan, Khaled M
AU  - Ramadan KM
FAU - Huang, Steven J T
AU  - Huang SJ
FAU - Toze, Cynthia L
AU  - Toze CL
FAU - Gillan, Tanya L
AU  - Gillan TL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120829
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
RN  - 0 (Immunoglobulin Heavy Chains)
RN  - FA2DM6879K (Vidarabine)
RN  - P2K93U8740 (fludarabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Cytogenetics
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Immunoglobulin Heavy Chains/*genetics
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/immunology/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Time Factors
MH  - *Translocation, Genetic
MH  - Vidarabine/analogs & derivatives/therapeutic use
EDAT- 2012/09/04 06:00
MHDA- 2013/01/11 06:00
CRDT- 2012/09/04 06:00
PHST- 2012/03/18 00:00 [received]
PHST- 2012/05/22 00:00 [revised]
PHST- 2012/05/23 00:00 [accepted]
PHST- 2012/09/04 06:00 [entrez]
PHST- 2012/09/04 06:00 [pubmed]
PHST- 2013/01/11 06:00 [medline]
AID - S2210-7762(12)00152-4 [pii]
AID - 10.1016/j.cancergen.2012.05.011 [doi]
PST - ppublish
SO  - Cancer Genet. 2012 Oct;205(10):523-7. doi: 10.1016/j.cancergen.2012.05.011. Epub 
      2012 Aug 29.